Lenakast 10mg Capsule

Lenakast 10mg Capsule is an immunomodulatory drug derived from thalidomide as it contains active ingredient Lenalidomide. It is a prescription-based anticancer medicine used to treat Multiple Myeloma, Myelodysplastic Syndromes, and Mantle Cell Lymphoma.

This medicine contains immunomodulatory and antiangiogenic properties, and it works by affecting the functioning of the immune system & slowing down the growth of cancer cells. Take it in the exact dosage prescribed by the doctor.​

• Multiple Myeloma
• Myelodysplastic Syndromes
• Mantle Cell Lymphoma

Like any other anticancer medicine, Lenakast 10mg Capsule also has some adverse effects on the body, and most of them are manageable without special medical attention.

Some common side effects include:

• Nausea
• Rash
• Headache
• Breathlessness
• Dizziness
• Fatigue
• Decreased white blood cell count (neutrophils)
• Joint pain
• Itching
• Diarrhea
• Low blood platelets
• Peripheral edema
• Cough
• Back pain
• Upper respiratory tract infection
• Decreased appetite
• Nasopharyngitis (inflammation of the throat and nasal passages)

Seek medical attention immediately in case of any severe side effects.

• The dosage of the capsule is usually decided by the doctor as per the patient's health condition, stage & type of cancer. Lenakast 10mg Capsule should be swallowed as a whole with water. It should not be crushed, chewed, or cut.
• In case you experience symptoms of overdose, immediately call your doctor or any other medical emergency helpline.​​
  

• Lenakast 10mg Capsule is an anti-cancer medication. It works by enhancing the immune system's functioning, which indirectly attacks the cancer cells. It prevents the growth of new blood vessels within the tumor.
• It also restricts the production of chemical messengers (cytokines and growth factors), which are responsible for the growth of cancer cells.​​
  

• Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., ... & Richardson, P. G. (2016). Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. New England Journal of Medicine, 374(17), 1621-1634. https://pubmed.ncbi.nlm.nih.gov/27119237/
• Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., ... & Ebert, B. L. (2014). Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science, 343(6168), 301-305. https://pubmed.ncbi.nlm.nih.gov/24292625/
• Gribben, J. G., Fowler, N., & Morschhauser, F. (2015). Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. Journal of Clinical Oncology, 33(25), 2803-2811. https://pubmed.ncbi.nlm.nih.gov/26195701/
• McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., ... & Linker, C. (2012). Lenalidomide after stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 366(19), 1770-1781. https://pubmed.ncbi.nlm.nih.gov/22571201/
• Anderson, K. C. (2005, October). Lenalidomide and thalidomide: mechanisms of action—similarities and differences. In Seminars in Hematology (Vol. 42, pp. S3-S8). WB Saunders. https://pubmed.ncbi.nlm.nih.gov/16344099/